NASDAQ:GPCR Structure Therapeutics (GPCR) Stock Forecast, Price & News $50.42 +12.95 (+34.56%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$48.55▼$65.5150-Day Range$26.49▼$50.4252-Week Range$20.80▼$65.51Volume9.97 million shsAverage Volume545,955 shsMarket Capitalization$1.93 billionP/E RatioN/ADividend YieldN/APrice Target$59.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Structure Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside18.0% Upside$59.50 Price TargetShort InterestBearish6.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.60Based on 20 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.88) to ($0.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.37 out of 5 starsMedical Sector930th out of 971 stocksPharmaceutical Preparations Industry427th out of 445 stocks 2.5 Analyst's Opinion Consensus RatingStructure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $59.50, Structure Therapeutics has a forecasted upside of 18.0% from its current price of $50.42.Amount of Analyst CoverageStructure Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.58% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Structure Therapeutics has recently decreased by 4.98%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldStructure Therapeutics does not currently pay a dividend.Dividend GrowthStructure Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GPCR. Previous Next 2.0 News and Social Media Coverage News SentimentStructure Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Structure Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for GPCR on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Structure Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions46.12% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Structure Therapeutics are expected to decrease in the coming year, from ($0.88) to ($0.92) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Structure Therapeutics (NASDAQ:GPCR) StockStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.Read More GPCR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GPCR Stock News HeadlinesOctober 1, 2023 | americanbankingnews.comStructure Therapeutics (NASDAQ:GPCR) PT Raised to $79.00 at Jefferies Financial GroupOctober 1, 2023 | americanbankingnews.comStructure Therapeutics (NASDAQ:GPCR) PT Raised to $97.00October 1, 2023 | Behind the Markets (Ad)U.S. Loses to China in Shocking WAR GAMES=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>October 1, 2023 | americanbankingnews.comStructure Therapeutics (NASDAQ:GPCR) Sets New 52-Week High on Analyst UpgradeSeptember 30, 2023 | msn.comStructure Therapeutics surges as early data from obesity pill tops expectationsSeptember 30, 2023 | msn.comStructure Therapeutics surges after early-stage data for oral weight loss agentSeptember 30, 2023 | msn.comGLP-1 drug developer Carmot Therapeutics reportedly mulling IPO or buyoutSeptember 29, 2023 | msn.comLeerink sees Structure Therapeutics stock as "undervalued"October 1, 2023 | Behind the Markets (Ad)U.S. Loses to China in Shocking WAR GAMES=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>September 29, 2023 | finance.yahoo.comStructure Soars 35% As Newcomer Takes On Behemoths Lilly, Novo In Obesity TreatmentSeptember 29, 2023 | finanznachrichten.deStructure Therapeutics Inc.: Structure Therapeutics Announces $300 Million Private Placement Equity FinancingSeptember 29, 2023 | msn.comStructure's Obesity Pill Could Challenge Lilly, Novo, Small Study SuggestsSeptember 29, 2023 | reuters.comStructure Therapeutics surges on promising early stage obesity drug dataSeptember 29, 2023 | finance.yahoo.comWhy Shares of Structure Therapeutics Are Soaring on FridaySeptember 29, 2023 | tmcnet.comStructure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program UpdateSeptember 29, 2023 | benzinga.comWhy Is Obesity Focused Structure Therapeutics Stock Trading Higher Today?September 29, 2023 | msn.comStructure Therapeutics shares surge after positive results in weight-loss trial, $300 million private placementSeptember 29, 2023 | markets.businessinsider.comStructure Therapeutics Sets $300 Mln Private Placement Equity FinancingAugust 31, 2023 | businesswire.comSepterna Bolsters Leadership Team as the Company Advances its Multi-Product Pipeline Toward Clinical StudiesAugust 28, 2023 | seekingalpha.comStructure Therapeutics: Recent IPO With Large ValuationAugust 11, 2023 | msn.comStructure Therapeutics GAAP EPS of -$0.20August 11, 2023 | markets.businessinsider.comStructure Therapeutics Reports Second Quarter 2023 Financial Results and Recent HighlightsAugust 11, 2023 | finance.yahoo.comStructure Therapeutics Reports Second Quarter 2023 Financial Results and Recent HighlightsAugust 3, 2023 | finance.yahoo.comStructure Therapeutics Appoints Ted W. Love, M.D., to Board of DirectorsAugust 2, 2023 | thestreet.comQualcomm Unveils New Corporate StructureJuly 28, 2023 | cnbc.comThis under-the-radar biotech could be the next way to play the obesity drug boomJuly 17, 2023 | finance.yahoo.comCumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR TargetsSee More Headlines Receive GPCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GPCR Company Calendar Last Earnings8/10/2023Today10/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GPCR CUSIPN/A CIK1888886 Webwww.structuretx.com Phone628-229-9277FaxN/AEmployees77Year FoundedN/APrice Target and Rating Average Stock Price Forecast$59.50 High Stock Price Forecast$97.00 Low Stock Price Forecast$33.00 Forecasted Upside/Downside+18.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio15.20 Quick Ratio15.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares38,270,000Free FloatN/AMarket Cap$1.93 billion OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Raymond C. Stevens Ph.D. (Age 59)CEO & Director Comp: $747.33kDr. Yingli Ma Ph.D. (Age 49)Chief Technology Officer Comp: $497.58kDr. Mark A. Bach M.D. (Age 66)Ph.D., Chief Medical Officer Comp: $628.37kMr. Jun S. Yoon (Age 45)Co- Founder, CFO & Sec. Dr. Xichen Lin Ph.D. (Age 49)Chief Scientific Officer Mr. Tony PengSr. VP of LegalDr. Hui Lei Ph.D.Sr. VP of ChemistryMs. Melita Sun Jung (Age 46)Chief Bus. Officer Dr. Fang Zhang Ph.D.Exec. VP & Head of BiologyMs. Lani IbarraSr. VP of Clinical Devel. OperationsMore ExecutivesKey CompetitorsCatalyst PharmaceuticalsNASDAQ:CPRXSummit TherapeuticsNASDAQ:SMMTAmneal PharmaceuticalsNYSE:AMRXAmylyx PharmaceuticalsNASDAQ:AMLXTG TherapeuticsNASDAQ:TGTXView All CompetitorsInstitutional OwnershipBarclays PLCBought 1,132 shares on 9/21/2023Ownership: 0.003%Davidson Kempner Capital Management LPSold 1,000 shares on 9/12/2023Ownership: 0.000%Point72 Asset Management L.P.Bought 81,138 shares on 8/15/2023Ownership: 1.126%Citadel Advisors LLCSold 16,624 shares on 8/15/2023Ownership: 0.914%State Street CorpBought 11,460 shares on 8/14/2023Ownership: 0.030%View All Institutional Transactions GPCR Stock - Frequently Asked Questions Should I buy or sell Structure Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Structure Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GPCR shares. View GPCR analyst ratings or view top-rated stocks. What is Structure Therapeutics' stock price forecast for 2023? 6 brokers have issued 1 year target prices for Structure Therapeutics' shares. Their GPCR share price forecasts range from $33.00 to $97.00. On average, they anticipate the company's stock price to reach $59.50 in the next twelve months. This suggests a possible upside of 18.0% from the stock's current price. View analysts price targets for GPCR or view top-rated stocks among Wall Street analysts. How have GPCR shares performed in 2023? Structure Therapeutics' stock was trading at $26.00 on January 1st, 2023. Since then, GPCR shares have increased by 93.9% and is now trading at $50.42. View the best growth stocks for 2023 here. How were Structure Therapeutics' earnings last quarter? Structure Therapeutics Inc. (NASDAQ:GPCR) posted its quarterly earnings results on Thursday, August, 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01. What ETF holds Structure Therapeutics' stock ? Virtus LifeSci Biotech Clinical Trials ETF holds 3,513 shares of GPCR stock, representing 0.96% of its portfolio. When did Structure Therapeutics IPO? (GPCR) raised $150 million in an initial public offering on Friday, February 3rd 2023. The company issued 10,740,000 shares at $13.00-$15.00 per share. What is Structure Therapeutics' stock symbol? Structure Therapeutics trades on the NASDAQ under the ticker symbol "GPCR." When did the company's lock-up period expire? Structure Therapeutics' lock-up period expired on Wednesday, August 2nd. Structure Therapeutics had issued 10,740,000 shares in its initial public offering on February 3rd. The total size of the offering was $161,100,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period. How do I buy shares of Structure Therapeutics? Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Structure Therapeutics' stock price today? One share of GPCR stock can currently be purchased for approximately $50.42. How much money does Structure Therapeutics make? Structure Therapeutics (NASDAQ:GPCR) has a market capitalization of $1.93 billion. How can I contact Structure Therapeutics? The official website for the company is www.structuretx.com. The company can be reached via phone at 628-229-9277 or via email at ir@structuretx.com. This page (NASDAQ:GPCR) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.